Dr Ian Chau (Royal Marsden Hospital, London, UK) joins us at ASCO 2021 to discuss the pivotal first results of the global phase III CheckMate 648 trial, which revealed first-line nivolumab regimens improve survival in esophageal squamous cell carcinoma.
The abstract (LBA4001) ‘Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study’ was presented at the 2021 ASCO Annual Meeting.
DOI: 10.1200/JCO.2021.39.15_suppl.LBA4001 Journal of Clinical Oncology 39, no. 18_suppl
Clinical Trials Reference number: NCT03143153
Questions
- What are the limitations of current first-line treatments for advanced esophageal squamous cell carcinoma? (00:12-00:56)
- What were the aims, design and eligibility criteria of the Checkmate 648 study? (00:56-02:13)
- What were the overall and progression-free survival outcomes, and how do these compare to those seen previously? (02:13-05:47)
- What were the safety profiles of the two combined treatments? (05:47-06:37)
- When these treatments become available, what factors should influence the choice of nivolumab plus chemotherapy or ipilimumab? (06:37-08:37)
Disclosures: Ian Chau is a member of the advisory board for Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics, Astra-Zeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte, Astella, GSK, Sotio and Eisai. He has received research funding from Eli-Lilly and Janssen-Cilag and honorarium from Eli-Lilly, Eisai and Servier.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 ASCO Annual Meeting.
